News from k-v pharmaceutical company A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-NMS:OGXI)

Aug 20, 2015, 07:30 ET
Eli Lilly and Company logo.

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This is a...

Aug 10, 2015, 18:36 ET

FDA Accepts a Supplemental New Drug Application for Review of Brintellix® (vortioxetine) Clinical Trial Data That Assessed Cognitive Function in Patients with Major Depressive Disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has...

Aug 03, 2015, 13:32 ET

Par Pharmaceutical Announces Second Quarter 2015 Conference Call

Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Friday, August 7, 2015 at 9:00 a.m. EDT to review its...

Aug 03, 2015, 11:00 ET

FDA Approves The First 3D Printed Drug Product

 Aprecia Pharmaceuticals Company today announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM® levetiracetam for...

Jul 30, 2015, 10:21 ET

Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA

Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the study to fulfill the post-marketing commitment and...

Jul 30, 2015, 02:00 ET

Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1%

Guidance for FY2015 confirmed, including Core Earnings and Core EPS   Highlights of Q1 results ...

Jul 29, 2015, 11:40 ET

Par Pharmaceutical Begins Shipment of Generic Megace® ES

 Par Pharmaceutical Companies, Inc. today announced that it has begun shipping the authorized generic version of Par Specialty Pharmaceutical's...

Jul 27, 2015, 06:00 ET

DNDi and Takeda Collaborate for the Lead Optimization for Aminopyrazole Series for Visceral Leishmaniasis

Drugs for Neglected Diseases initiative (Headquarters: Geneva, Switzerland; Executive Director: Bernard Pécoul, Doctor; "DNDi") and Takeda...

Jun 05, 2015, 17:15 ET

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Takeda Pharmaceutical Company Limited, ("Takeda") today announced additional post-hoc analyses from the global EXAMINE (EXamination of...

May 27, 2015, 07:30 ET
Eli Lilly and Company logo.

Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association's 75th Scientific Sessions®

 The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim (BIPI) and Eli Lilly and Company (NYSE:...

May 27, 2015, 07:00 ET

Par Pharmaceutical Receives Favorable Appeals Court Ruling in Generic Exelon® Patch Litigation

Par Pharmaceutical Companies, Inc. today announced that the United States Court of Appeals for the Federal Circuit has upheld the U.S. District...

May 26, 2015, 10:19 ET

Par Specialty Pharmaceuticals Launches Cortisporin®-TC Otic Suspension

 Par Specialty Pharmaceuticals, a division of Par Pharmaceutical, Inc., today announced the launch of Cortisporin®-TC Otic Suspension...

May 21, 2015, 10:00 ET

Canadians lagging well behind similar countries on access to new medicines: report

OTTAWA, May 21, 2015 /CNW/ - Canadians face wait times of over 460 days in order to get access to new, potentially lifesaving medicines in...

May 15, 2015, 02:26 ET

Takeda Reports Top Line Results in Line With Guidance, With Underlying Growth of +2.8% EPS Affected by One-time Charges in FY2014 Back to Profitable Growth from FY2015 Onward

Operational guidance met  - Underlying revenue +2.8% year-over-year, in line with guidance (reported revenue growing +5.1% to 1,777.8...

May 11, 2015, 08:00 ET

Johnson & Johnson Expands IP Policy to Create Broad Access in 128 Countries for Development of New and Optimized HIV Medicine Formulations for Children Living with HIV

 Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have furthered their commitment to improve the health of...

May 07, 2015, 09:06 ET

Par Pharmaceutical Announces First Quarter 2015 Conference Call

 Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Wednesday, May 13, 2015 at 10:00 a.m. EDT to review...

Apr 16, 2015, 23:11 ET
Researchers at Takeda and CiRA at Kyoto University, Japan, will collaborate on developing game-changing therapeutics by applying iPS cell and related technologies to pharmaceutical R&D activities, such as drug discovery, cell therapy and drug safety. CiRA Director Shinya Yamanaka, a Nobel laureate for his work on iPS cells, will direct the program, while Takeda provides long-term funding, recommendations on research management, and facilities at Shonan Research Center.

CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research

 Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today that...

Apr 14, 2015, 19:00 ET

FDA Advisory Committee Reviews Takeda's Alogliptin EXAMINE Cardiovascular Safety Outcomes Trial

Takeda Pharmaceuticals U.S.A. Inc. and Takeda Pharmaceutical Company Limited, ("Takeda") today announced that members of the Endocrinologic and...

Apr 13, 2015, 08:40 ET

Takeda Announces Appointment of New President of U.S. Business Unit

 Takeda Pharmaceutical Company Limited ("Takeda"), and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA")...

Apr 01, 2015, 08:03 ET

Rx&D responds to PMPRB report: overall impact of medicines must always be considered

OTTAWA, April 1, 2014 /CNW/ - Canada's Research-Based Pharmaceutical Companies (Rx&D) acknowledges the Patented Medicines Prices Review Board's...